HIV Licensed Products Clause Samples
The "HIV Licensed Products" clause defines which products are covered under a license agreement specifically for HIV-related technologies or treatments. It typically outlines the scope of products, such as drugs, therapies, or diagnostic tools, that utilize the licensed intellectual property and are intended for the prevention, diagnosis, or treatment of HIV. By clearly specifying what constitutes an HIV Licensed Product, this clause ensures both parties understand the boundaries of the license, preventing disputes over what is included and facilitating proper royalty calculations and compliance.
HIV Licensed Products. Gilead shall itself, or through its Affiliates or sublicensees, use Commercially Reasonable Efforts to Commercialize following Regulatory Approval [***] HIV Licensed Product in the Field in: [***].
HIV Licensed Products. Beginning at such time as the first HIV Licensed Product becomes Development-Ready, Gilead shall itself, or through its Affiliates or sublicensees, use Commercially Reasonable Efforts to Develop for purposes of achieving Regulatory Approval [***] HIV Licensed Product in: [***].
HIV Licensed Products. (i) Effective upon the Effective Date, (A) the HIV Collaboration Term of the HIV Collaboration Program shall terminate; and (B) Hookipa or one of its Affiliates shall take over clinical development responsibility for the HIV Development Program until completion of the HIV Development Plan. Within [***] weeks after completion of all Development activities under the HIV Development Plan, Hookipa shall provide Gilead with the Option Exercise Data Package for the HIV Development Program. No later than [***] Business Days after receipt by Gilead of the proposed Option Exercise Data Package, Gilead may notify Hookipa that Gilead considers the proposed Option Exercise Data Package to be deficient or incomplete in any respect, in which case, in the event Hookipa agrees with Gilead’s determination (or it is determined through the dispute resolution procedures in the immediately-following sentence) that an initially proposed or revised Option Exercise Data Package is deficient or incomplete in any respect (i) Hookipa will promptly correct the deficiency or incompleteness, and (ii) the Option Period will be tolled for the time period beginning on the date on which Gilead so notifies Hookipa and ending on the date on which Hookipa has corrected the deficiency or incompleteness. In the event that Hookipa disagrees with Gilead’s determination that an initially proposed or revised Option Exercise Data Package is deficient or incomplete in any respect, (x) Hookipa will promptly notify Gilead of such disagreement in writing, (y) the Dispute shall be resolved as a Selected Dispute in accordance with Section 18.5, except that any reference to [***] days in Section 18.5 shall for purposes of resolving such Selected Dispute be changed to [***] Business Days, and (z) the Option Period will be tolled for the time period beginning on the date the Selected Dispute is referred to the Alliance Managers pursuant to Section 18.5(a) (Initial Dispute Resolution Process) and ending on the date on which the arbitrators deliver their decision (or earlier date on which the Parties are able to resolve such Selected Dispute). In addition, Gilead may, within [***] Business Days after delivery of the proposed Option Exercise Data Package pursuant to this Section 2.3(b)(i), request from Hookipa additional data, results or other information [***], in each case, that Gilead reasonably deems necessary to consider for the purposes of determining whether to exercise the Option. Hookipa shall use reas...